ライフサイエンスコーパス: distribution volume

1 ls were used to estimate pancreas and spleen distribution volume.

2 t brain uptake can be robustly calculated as distribution volume.

3 odeling was used to estimate the radioligand distribution volume.

4 binding) to cerebellum (nonspecific binding) distribution volume.

5 occupancy by scopolamine and nondisplaceable distribution volume.

6 sponding to an approximately 90% decrease in distribution volume.

7 analysis method (MA1) to calculate regional distribution volume.

8 to evaluate (11)C-AS2471907 nondisplaceable distribution volume.

9 y, corresponding to changes in [(11) C]PBR28 distribution volume.

10 ypoxia (k3), perfusion (K1), and (18)F-FMISO distribution volume.

11 of tumor hypoxia, perfusion, and radiotracer distribution volume.

12 levetiracetam occupancy and nondisplaceable distribution volume.

13 ith regional tracer binding quantified using distribution volume.

14 del to derive reliable estimates of regional distribution volumes.

15 n volume, 0.182 vs 0.244; median whole liver distribution volume, 0.175 vs 0.207; P = .008).

16 ntly increased after treatment (median tumor distribution volume, 0.182 vs 0.244; median whole liver

17 Distribution volume (130 min) was lower by 30%-35% in th

18 atistical analysis examined changes in total distribution volume after treatment with AZD3241 compare

19 sion and Hamilton Anxiety Rating scales, and distribution volume also was assessed.

20 y optimal methods for derivation of regional distribution volume and binding potential and to determi

21 l analysis yielded reliable estimates of the distribution volume and could separate newly diagnosed h

22 ector by constraining the binding potential, distribution volume and dissociation rate constant to im

23 umors liver metastases; a lower pretreatment distribution volume and high arterial flow fraction was

24 No relationship between [(11)C]NOP-1A distribution volume and other clinical measures (includi

25 pretreatment did not affect cerebellar total distribution volume and reduced total distribution volum

26 d to compute parameters including fractional distribution volume and the arterial flow fraction.

27 [(123)I]5-IA SPECT images were converted to distribution volume and were analyzed using regions of i

28 Regional distribution volumes and binding potentials were calcula

29 Kinetic models were used to estimate distribution volumes and binding potentials, for which t

30 Total distribution volumes and nondisplaceable binding potenti

31 A SPECT images were converted to equilibrium distribution volumes and were analyzed using regions of

32 0.4-1.0% for arterial fraction, 0.5-1.4% for distribution volume, and 0.0% for mean transit time.

33 1.1-2.1% for arterial fraction, 0.5-1.3% for distribution volume, and 0.2-1.8% for mean transit time.

34 and k3-surrogates for perfusion, (18)F-FMISO distribution volume, and hypoxia-mediated entrapment, re

35 on, and arterial flow but lower portal flow, distribution volume, and mean transit time than did the

36 rterial flow, portal flow, total blood flow, distribution volume, and mean transit time) parameters w

37 er transport rate constant k(1), equilibrium distribution volumes, and influx rate constant K than di

38 e benzodiazepine receptor binding measure of distribution volume are consistent with fewer benzodiaze

39 hought to be small (<10%), because values of distribution volume are stable during 60-120 min and var

40 A framework was developed in which dose distribution volumes are uploaded onto the medical cente

41 (trans-4-fluorocyclohexanecarboxylic acid), distribution volumes attributed to the parent radioligan

42 ference tissue-based methods to estimate the distribution volume, binding potential (BPND), and SUVR.

43 The cerebellum had the lowest distribution volume, but the time-activity curve data co

44 nitoring, correlation of infused volume with distribution volume, clearance of infused liposome conta

45 The relationships between (123)I-iomazenil distribution volume, clinical features of alcohol depend

46 (18)F-FMISO distribution volume deviated from the expected value of

47 delivery and inducible nitric oxide synthase distribution volume did not significantly differ among g

48 The mean anterior cingulate cortex distribution volume differed across groups (F55 = 3.4; P

49 availability was quantified as VT/fP (total distribution volume divided by free plasma concentration

50 but statistically significant reductions in distribution volume (DV) of both (R)- and (S)-[11C]nicot

51 By comparing the distribution volume (DV) of different regions to the cer

52 ficantly reduced FMZ ligand influx (K1), FMZ distribution volume (DV), and 1CMRg1c bilaterally in the

53 fraction (ART), portal venous fraction (PV), distribution volume (DV), and mean transit time (MTT) of

54 Distribution volume (DV), mean transit time (MTT), and p

55 analysis was used to calculate (18)F-FEAnGA distribution volumes (DV(Logan)) in various brain areas.

56 (DV) of different regions to the cerebellum distribution volume, DV(ratio)-1, which is proportional

57 binding site density (tissue-to-plasma DTBZ distribution volume, DV) from the cerebral and plasma DT

58 an index of nigrostriatal terminal density (distribution volume; DV), also provide a measure of tran

59 The ratio of striatal-to-occipital distribution volume (DVR) was calculated directly by usi

60 ressure), and brain DA [reduced decreases in distribution volumes (DVs) of [(11)C]raclopride, althoug

61 analyzed using graphic analysis to give the distribution volumes (DVs) of different brain regions.

62 2-compartment model for estimation of tracer distribution volumes (DVs).

63 ma to brain transfer constant (K1), striatal distribution volume (DVstr) and DA D2 receptor availabil

64 ) and Logan plot slopes, a measure of tracer distribution volume (equilibrium tissue-to-plasma ratio)

65 The outcome measure was the total distribution volume, estimated with the invasive Logan g

66 ficant deviations between vascular blood and distribution volume estimates were found.

67 The ratio of the distribution volume for [11C]d-threo-methylphenidate in

68 ) x 10(-1) ml/g; n = 5] agreed well with the distribution volume for compartment 1 of the 3-compartme

69 se of peripheral and splanchnic interstitial distribution volumes for [(14)C]inulin.

70 The total distribution volumes for multiple cortical regions and t

71 ided good fits to the PET data, and regional distribution volumes from the latter correlated well wit

72 Distribution volume image data were analyzed by means of

73 cipants, the NFL players showed higher total distribution volume in 8 of the 12 brain regions examine

74 Regional [(11)C]NOP-1A distribution volume in alcohol dependence was not signif

75 g revealed two large excursions in which the distribution volume in alcoholic patients was significan

76 s by examining the stability of the apparent distribution volume in DAT-rich (striatum) and DAT-poor

77 total distribution volume and reduced total distribution volume in other regions to a level comparab

78 [(11)C]NOP-1A distribution volume in regions of interest (including th

79 Main Outcome Measure Relative distribution volume in regions of interest was used as t

80 The distribution volume in the cerebellum increased up to 1.

81 onsistent with the rodent data, the apparent distribution volume in the cerebellum of both humans and

82 uantifying the following for 5-FU in tumors: distribution volume in the extracellular space, cell tra

83 There was no overall change in total distribution volume in the placebo group (n = 6).

84 lability was measured using the ratio of the distribution volume in the putamen to that in the cerebe

85 ning times required to derive time-invariant distribution volumes in all regions were comparable for

86 Bmax/Kd (ratio of the distribution volumes in striatum to that in cerebellum m

87 Total distribution volumes in the cerebellum were 6.91 +/- 0.6

88 The distribution volumes in the thalamus were measured in th

89 (18)F-FDG distribution volume increased with infiltrating neutroph

90 challenge with receptor ligands is that the distribution volume is confined to tissues with tracer u

91 challenge with receptor ligands is, that the distribution volume is confined to tissues with tracer-u

92 Benzodiazepine receptor distribution volume is significantly lower in several co

93 ire duration of imaging, in which delay, K1, distribution volume, k3, and k4 were optimized using a n

94 ron emission tomography measured MAO-A total distribution volume (MAO-A VT), an index of MAO-A densit

95 aging scans) and by a pixel-by-pixel method (distribution volume maps were analyzed with statistical

96 a dynamic PET scan to measure [(11)C] MePPEP distribution volume (ml/cm(3)) to index CB1R availabilit

97 ion of 12% EC in ethanol created the largest distribution volume, more than eight-fold that of pure e

98 he AD3241 treatment group (n = 18) the total distribution volume of (11)C-PBR28 binding to translocat

99 retreatment with LY2886721 reduced the total distribution volume of (18)F-PF-06684511 by 48%-80% depe

100 f the ratio of (111)In/(18)F to the apparent distribution volume of (99m)Tc-DTPA.

101 ic modeling of binding potentials revealed a distribution volume of 334 in cerebral blood that droppe

102 resulted in an increase in the nanoparticle distribution volume of 51% and 123%, respectively.

103 l contribution of MR(FDG), blood volume, and distribution volume of [(18)F]FDG in infectious lesions.

104 They measured the distribution volume of benzodiazepine receptors in 11 re

105 with the [11C]raclopride data to derive the distribution volume of D2 receptors.

106 ance [ANOVA]), indicating an increase in the distribution volume of Gd-DTPA-BMA in postischemic myoca

107 cement of myocardial necrosis is the greater distribution volume of injured myocardium compared with

108 lood-to-brain transfer constant, Ki, and the distribution volume of mobile protons, Vp) of 15 out of

109 ution volume of the region of interest minus distribution volume of the cerebellum.

110 d a volume-of-interest basis using the total distribution volume of the radioligand (18)F-3-fluoro-5-

111 ulated with the formula: binding potential = distribution volume of the region of interest minus dist

112 This would reduce distribution volume of therapeutics, and consequently mi

113 There was no significant correlation between distribution volumes of (11)C-tariquidar or (11)C-elacri

114 s of (11)C-tariquidar or (11)C-elacridar and distribution volumes of (R)-(11)C-verapamil in different

115 -euglycemic clamps, transport parameters and distribution volumes of [(14)C]inulin were determined in

116 The fractional distribution volumes of gadopentetate dimeglumine and 99

117 nucleoid, and (ii) localization patterns and distribution volumes of sRNAs can differ from some large

118 F-FDG phosphorylation rate (P < 0.05) and to distribution volume (P < 0.01).

119 The median initial distribution volume predicted by the model was consisten

120 roaches yielded more stable estimates of the distribution volume ratio (1 + BPND), with coefficients

121 r characteristic analysis identified optimal distribution volume ratio (1.06) and standard uptake val

122 ng the specific distribution volume (VS) and distribution volume ratio (DVR [2TCM]) and a multilinear

123 Cortical 11C-Pittsburgh compound B (PiB) distribution volume ratio (DVR) and sampled iterative lo

124 quantification were explored including Logan distribution volume ratio (DVR) and static SUV ratio (SU

125 (18)F-NOS uptake was quantified as the distribution volume ratio (DVR) determined by Logan plot

126 ed using various SUVR approaches, as well as distribution volume ratio (DVR) estimated with (blDVR) o

127 reduction (20.6%; P < 0.0001) in the mGluR5 distribution volume ratio (DVR) in the gray matter of 14

128 t using [18F]DPA-714 TSPO PET, quantified as distribution volume ratio (DVR) in total, frontal lobe,

129 The SUVRs were compared with Logan graphical distribution volume ratio (DVR) measurements (35-90 min)

130 CAR90 best agreed with ART90 distribution volume ratio (DVR) measures across brain re

131 Microglial activation was evaluated as the distribution volume ratio (DVR) of (11)C-PK11195 from dy

132 reference tissue method was used to generate distribution volume ratio (DVR) parametric maps for a su

133 Regional TSPO availability was measured as a distribution volume ratio (DVR) relative to the caudate

134 egion, was used to estimate various regional distribution volume ratio (DVR) values in the brain befo

135 RTM) and SRTM2; the Logan graphical analysis distribution volume ratio (DVR) was calculated for 30-15

136 n-of-interest analysis was performed and the distribution volume ratio (DVR) was computed for striatu

137 Distribution volume ratio (DVR) was estimated using full

138 Distribution volume ratio (DVR) was estimated using full

139 C-PBR28 PET total volume of distribution and distribution volume ratio (DVR) were estimated using 2-t

140 In vivo binding was evaluated using the distribution volume ratio (DVR) with respect to a refere

141 tention that included compartmental modeling distribution volume ratio (DVR), arterial- and reference

142 eta) in vivo is often accomplished using the distribution volume ratio (DVR), based on a simplified r

143 Plasma-input Logan distribution volume ratio (DVR)-1 values agreed well wit

144 ts in that study, and measured the effective distribution volume ratio (EDVR) of [(18)F]DOPA influx r

145 lar amyloid measured by global mean cortical distribution volume ratio (P=0.075) and within the precu

146 ormal-tissue ratio (tau = 0.07, P = 0.56) or distribution volume ratio (tau = 0.26, P = 0.14).

147 etention was significantly increased in CAA (distribution volume ratio 1.18 +/- 0.06) relative to hea

148 retest variability was less than 15% for the distribution volume ratio and 12% for the radioactivity

149 ratio (r = 0.89; P = 0.001) but not between distribution volume ratio and either PR status or standa

150 We quantified the [11C]PiB distribution volume ratio and standardized uptake value

151 there was a significant correlation between distribution volume ratio and T/N ratio (r = 0.89; P = 0

152 The distribution volume ratio and the standardized uptake va

153 Normal-appearing white matter distribution volume ratio at baseline was correlated wit

154 Good agreement was found between the distribution volume ratio calculated using the graphic t

155 The resulting distribution volume ratio correlated with a low bias tow

156 Tumor-to-normal-tissue ratios and tumor distribution volume ratio did not correlate with Ki-67 (

157 Distribution volume ratio estimated by the Logan referen

158 on of (18)F-FEOBV correlated highly with the distribution volume ratio estimates from reference tissu

159 Distribution volume ratio estimates obtained using compa

160 The distribution volume ratio for the basal ganglia was then

161 At 12 mo, the Logan distribution volume ratio for the FC was 1.03 and 0.93 (

162 the amyloid-positive group with cortical PiB distribution volume ratio greater than 1.2.

163 A and AD subjects were PiB-positive, both by distribution volume ratio measurements and by visual ins

164 PET data analysis employed the distribution volume ratio method (DVR) in which the cere

165 implified reference tissue model (SRTM) with distribution volume ratio minus 1 (DVR - 1) for 60- and

166 Microglial activation was evaluated as distribution volume ratio of (11)C-(R)-PK11195.

167 ta level was measured according to a summary distribution volume ratio of frontal, lateral temporal a

168 S had an increased hippocampal [(18)F]PBR111 distribution volume ratio relative to healthy control su

169 (11)C-d-Methamphetamine distribution volume ratio was not substantially affected

170 rol subjects (p = .024), and the hippocampal distribution volume ratio was strongly correlated with t

171 Regional SUV ratio (SUVR) and distribution volume ratio were determined using the cere

172 al-appearing white matter was estimated as a distribution volume ratio with respect to a caudate pseu

173 ar monoaminergic transporter type 2 binding (distribution volume ratio) and thalamic and cortical ace

174 ominent contributor to this group (mean [SD] distribution volume ratio, 1.08 [0.05] for the SNAP grou

175 Voxel-wise maps of [(11) C]PIB distribution volume ratio, reflecting myelin content, we

176 g the baseline normal-appearing white matter distribution volume ratio, T2 lesion volume and normal-a

177 mal tissue and tumor to muscle, and relative distribution volume ratio.

178 ptake value ratio, and 11C-PiB were given as distribution volume ratio.

179 correlated with BDI scores and [(18)F]PBR111 distribution volume ratio.

180 81.0%, standard uptake value ratiolow 83.3%; distribution volume ratiohigh 61.9%, standard uptake val

181 lds (standard uptake value ratiohigh = 1.40, distribution volume ratiohigh = 1.20) that are more cons

182 iolow 95.8%; standard uptake value ratiolow, distribution volume ratiohigh and standard uptake value

183 compound-B positivity (typically at or above distribution volume ratiohigh and standard uptake value

184 nsitive than high thresholds (sensitivities: distribution volume ratiolow 81.0%, standard uptake valu

185 neuritic plaques, with similar specificity (distribution volume ratiolow 95.8%; standard uptake valu

186 olds (standard uptake value ratiolow = 1.21, distribution volume ratiolow = 1.08) that represent the

187 s that were nearly identical to the a priori distribution volume ratiolow and standard uptake value r

188 s assessed visually and quantitatively using Distribution Volume Ratios (DVR) estimated from non-inva

189 s assessed visually and quantitatively using distribution volume ratios (DVR) estimated from noninvas

190 Distribution volume ratios (DVR) of [(18) F]Nifene in wh

191 stigated for quantification of (18)F-MK-6240 distribution volume ratios (DVRs) in a subset of 19 part

192 o (SUVR) and the Logan plot result in biased distribution volume ratios (DVRs) in ligand-receptor dyn

193 urgh compound B positron emission tomography distribution volume ratios (DVRs).

194 y associated with higher striatal (11)C-DTBZ distribution volume ratios (least affected: r = 0.57, P

195 TSPO tracer (18)F-GE180, we then calculated distribution volume ratios after establishing a suitable

196 (18)F-ISO-1 was quantitated by SUV(max) and distribution volume ratios and was compared with ex vivo

197 n of (18)F-GE180, which correlated well with distribution volume ratios calculated from the entire re

198 ke value ratios calculated at late times and distribution volume ratios estimated with the reference

199 Distribution volume ratios for maternal and fetal brain

200 TBI showed significantly increased [11C]PiB distribution volume ratios in cortical gray matter and t

201 Increases in [11C]PiB distribution volume ratios in patients with TBI were see

202 rmine noradrenaline transporter density, and distribution volume ratios of noradrenaline transporter-

203 (11)C-PIB distribution volume ratios of regions of interest were e

204 The distribution volume ratios of the maternal striatum were

205 ional (11)C-PIB retention was quantitated as distribution volume ratios using Logan graphical analysi

206 Distribution volume ratios were calculated to quantify b

207 [11C]PIB distribution volume ratios were calculated using Logan g

208 TRODAT-1 distribution volume ratios, a reflection of DAT availabi

209 On the basis of mean cortical distribution volume ratios, participants were divided in

210 erize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Abeta b

211 The distribution volume reduction across nigrostriatal regio

212 omographic images were converted to units of distribution volume (regional activity/free (123)I-iomaz

213 the uptake in the brain can be quantified as distribution volume relative to concentrations of (18)F-

214 In responders, tumor and whole liver distribution volume significantly increased after treatm

215 enil revealed normal benzodiazepine receptor distribution volumes, similar to those seen in sporadic

216 this effect depends on the magnitude of the distribution volume, so that the bias is more pronounced

217 ients had significantly lower benzodiazepine distribution volume than comparison subjects in the fron

218 ection and residuals and resulted in greater distribution volumes than did no damping with the first

219 raphic method enables derivation of regional distribution volumes that are free from assumptions abou

220 Translocator protein total distribution volume (TSPO V(T)), measured with positron

221 Translocator protein density measured by distribution volume (TSPO VT) is increased in activated

222 The density of the enzyme was calculated as distribution volume using a 2-tissue-compartment model a

223 ility was quantified by the (18)F-FPEB total distribution volume using both voxel-by-voxel and volume

224 is technique was first optimized to maximize distribution volume, using tissue-simulating phantoms.

225 cer were found for transport k(1), influx K, distribution volume V(d), as well as early (6-10 min) an

226 The distribution volume (V (T) ) ranged from 0.4 to 4.8 mL.c

227 and multilinear analysis 1 to compute total distribution volume (V (T)) and binding potential (BP (N

228 ling methods were applied to calculate total distribution volume (V (T)) and nondisplaceable binding

229 ively large test-retest variability of total distribution volume (V (T)) estimates (15%).

230 a input function was applied to estimate the distribution volume (V (T)) of (R)-[(18)F]YH134.

231 Brain uptake was quantified as total distribution volume (V (T)) using the standard 2-tissue-

232 ts in the 42 healthy subjects (average Logan-distribution volume (V T) was 13.3+/-3.8 mL/cm(3) for fu

233 tes of glutamine pool size, specifically the distribution volume (V(D)) for (18)F-Gln, were more reli

234 olume (V(S)) and the nondisplaceable-binding distribution volume (V(ND)), differences in V(ND) across

235 Since V(T) is the sum of the ligand-specific distribution volume (V(S)) and the nondisplaceable-bindi

236 Total distribution volume (V(T)) and binding potentials (k3'/k

237 Distribution volume (V(T)) for [(18)F]-VAT was derived f

238 [(11)C]NOP-1A total distribution volume (V(T)) in 11 regions of interest wer

239 [(11)C]NOP-1A total distribution volume (V(T)) in the regions of interest we

240 d that receptor density can be quantified as distribution volume (V(T)) using the gold standard of co

241 Brain uptake was measured as total distribution volume (V(T)) using the Logan plot and meta

242 [(11)C]NOP-1A distribution volume (V(T)) was measured with kinetic ana

243 Distribution volume (V(T)) was measured with region of i

244 ility) were assessed for 3 outcome measures: distribution volume (V(T)), binding potential (BP), and

245 edures were used for calculation of regional distribution volume (V(T)), nondisplaceable binding pote

246 equate time for more accurate measurement of distribution volume (V(T)), which is the summation of re

247 Distribution volume (V(T); a measure of receptor density

248 Distribution volume (V(T); a measure of receptor density

249 terial input function, we measured the total distribution volume (V; specific plus nondisplaceable),

250 The estimated MIBG distribution volumes (V(d)) for transduced Jurkat, C6, a

251 (specific plus nondisplaceable compartments) distribution volumes (V(T)') agreed between bolus and B/

252 ood data were used to calculate steady-state distribution volumes (V(T)) during the baseline conditio

253 Regional distribution volumes (V(T)) were derived for 16 brain re

254 Total distribution volumes (V(T)) were derived using kinetic 2

255 ta and more robust derivations of the tissue distribution volumes (V(T), in mL/g) than a 2-tissue com

256 n clinical studies of TSPO, the ligand total distribution volume, V(T), is frequently the reported ou

257 MA1-derived distribution volume values were high (range, 10-81 mL/cm

258 was injected into Compartment 1, the initial distribution volume (Vd) of the antibody, which included

259 rmed in living brain (kloss); and the tracer distribution volume (Vd), which is an index of dopamine

260 9-yl)acetamide) to determine nondisplaceable distribution volume (VND) via Lassen occupancy plotting

261 rom the estimated Kd and the nondisplaceable distribution volume (VND).

262 orrected plasma data estimating the specific distribution volume (VS) and distribution volume ratio (

263 -compartment model fitted the data well, and distribution volume (VT) (mLcm(-3)) values ranged from 1

264 to arrive at reliable estimates of regional distribution volume (VT) and binding potential (BPND) wi

265 Parametric distribution volume (VT) and influx rate (K1) were compa

266 The [11C]PBR28 distribution volume (VT) corrected for free fraction (fP

267 the absence of group differences in SUV and distribution volume (VT) estimated with an arterial inpu

268 The distribution volume (Vt) for (18)F-UCB-H was calculated

269 ivated during neuroinflammation and the TSPO distribution volume (VT) is an index of TSPO density.

270 The total distribution volume (VT) of the tracer was significantly

271 Intersubject variation in the cerebellar distribution volume (VT) was clearly related to the TSPO

272 A weighted average of 11C-ER176 total distribution volume (VT) was computed across 11 a priori

273 With the lowest steady-state distribution volume (VT), determined in the corpus callo

274 11C-ER176 total distribution volume (VT), obtained with an arterial inpu

275 late 5 outcome measures in 14 brain regions: distribution volume (VT), VT normalized by fP (VT/fP), a

276 d as an increase in [(11)C]flumazenil tissue distribution volume (VT).

277 2T) models were evaluated to calculate total distribution volume (VT).

278 in a priori volumes of interest, with total distribution volume (VT/fP) being the measure of nAChR a

279 gs of each parametric method were optimized, distribution volumes (VT) obtained with Logan graphic an

280 gs of each parametric method were optimized, distribution volumes (VT) obtained with Logan graphic an

281 ssue-compartment modeling for calculation of distribution volumes (VT).

282 er across the BRB (K1, k2) and total retinal distribution volume VTDuring ABCB1 inhibition, retinal V

283 er across the BRB (K1, k2) and total retinal distribution volume VTResults: During ABCB1 inhibition,

284 (18)F-MK-6240 total distribution volume was approximately 2- to 3-fold highe

285 Total distribution volume was assessed by compartmental modeli

286 From the blocking scans, nondisplaceable distribution volume was determined to be 0.16 +/- 0.04 m

287 Ablations were monitored with CT and ethanol distribution volume was quantified.

288 The pretreatment whole liver distribution volume was significantly lower in responder

289 serum creatinine on clearance and weight on distribution volume was used.

290 Distribution volume was well identified ( approximately

291 related to benzodiazepine receptor binding (distribution volume) was obtained with single photon emi

292 equate time for more accurate measurement of distribution volume, we selected a scan duration (i.e.,

293 (18)F-FDG phosphorylation rate and distribution volume were calculated with a 4-compartment

294 The values of distribution volume were well identified and had relativ

295 Regional total distribution volumes were derived using the arterial inp

296 Distribution volumes were derived using the Logan graphi

297 Lower distribution volumes were found in the prefrontal cortex

298 The fractional distribution volumes were greater in infarcted myocardiu

299 noise is associated with underestimation of distribution volumes when data are analyzed with graphic

300 primary outcome parameter was [(18)F]FP-TZTP distribution volume, which is proportional to the produc